Capsida Biotherapeutics
Biotechnology Research • 
Thousand Oaks, California, United States • 51-100 Employees
Company overview
| Headquarters | 1290 Rancho Conejo Blvd, Newbury Park, CA 91320, US |
| Website | |
| Keywords | Biotechnology, Process Development, Gene Therapy, Biopharmaceuticals, Analytical Development, Protein Engineering, Aav Engineering, Aav Immunology |
| Founded | 2019 |
| Employees | 51-100 |
| Socials |
Key Contacts at Capsida Biotherapeutics
Denny Muha
Executive Director, Head Of Human Resources
Marsela Jorgolli
Executive Director
Sasha Bogdanovich
Executive Director, Clinical Development
Carrie Pedeferri
Executive Director Of Manufacturing
Bradley Wachtell
Associate Director, Business Operations
Shane Wells
Executive Director, Head Of Engineering And Facilities Operations
Mark H. Chin
Director, Quantitative Biology And Data Sciences
Pasha Tchourilov
Director, Technical Services
Madhuri Borde
Executive Director, Market Intelligence And Alliance Management
Allison Knoll
Director Preclinical Research
Capsida Biotherapeutics Email Formats
Capsida Biotherapeutics uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@capsida.com), used 74.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@capsida.com | 76% |
{first name}.{last name} | john.doe@capsida.com | 22.8% |
{first initial}-.{last name} | j-.doe@capsida.com | 1.3% |
About Capsida Biotherapeutics
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
Capsida Biotherapeutics revenue & valuation
| Annual revenue | $2,000,000 |
| Revenue per employee | $23,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $6,400,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Capsida Biotherapeutics has 42 employees across 8 departments.
Departments
Number of employees
Capsida Biotherapeutics Tech Stack
Discover the technologies and tools that power Capsida Biotherapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Analytics
Video players
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
Tag managers
Reverse proxies
Canada
Switzerland
Australia
Frequently asked questions
4.8
40,000 users
